Cardiovascular
Corvia Medical’s atrial shunt therapy shows promise in randomised clinical trial
Corvia Medical has announced positive safety and efficacy results from its REDUCE LAP-HF II randomised Phase III trial. The data,…
Abbott tout results from AVEIR DR pacemaker trial
Abbott has unveiled positive late-breaking results from a study (NCT05252702) investigating the safety and performance of its new dual-chamber leadless…
Salubris reports positive results from Phase Ib trial of HFrEF therapy
Salubris Biotherapeutics has reported positive updated results from its ongoing Phase Ib clinical trial evaluating JK07 in heart failure with…
Neurimmune reports Phase I study results of ATTR-CM drug
Neurimmune has reported primary results from the Phase I clinical trial of NI006, a human monoclonal antibody designed for the…
Elixir’s coronary implant device meets primary endpoint at 12-months
Elixir Medical has reported positive findings from a clinical trial investigating its company’s DynamX Coronary Drug-Eluting Bioadaptor compared to a…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Pipeline Moves: Hengrui Medicine Phase III breast cancer termination lowers approval prospects
This week on Pipeline Moves, we start by investigating terminations of a Phase III trial in breast cancer, a Phase…
Acesion Pharma reports positive preclinical data for AF therapy
Danish pharmaceutical firm Acesion Pharma has reported positive pre-clinical data for its second-generation oral SK channel inhibitor AP31969. AP31969 is…
Cytokinetics doses patients in cardiac myosin inhibitor trial
US-based biopharmaceutical company Cytokinetics has dosed the first subjects in a Phase I clinical trial of CK-4021586 (CK-586), a cardiac…
Rocket Pharma receives FDA IND clearance for ACM Phase I trial
Rocket Pharmaceuticals’ investigational new drug (IND) application for a Phase I clinical trial of RP-A601, an AAV.rh74-based gene therapy candidate…
Silence completes patient enrolment in zerlasiran Phase II trial
Silence Therapeutics has completed enrolment of patients in the ALPACAR-360 Phase II trial of zerlasiran (SLN360) to treat patients with…